Comparison of single-dose and steady-state nadolol plasma concentrations.
The pharmacokinetics of nadolol have been previously reported to be linear between single and steady-state dosing. Data from a study in our laboratory suggested greater than expected beta-blockade with nadolol at steady state. Because the early potency studies were single-dose studies, we hypothesized there was a nonlinearity in nadolol pharmacokinetics which produced higher than expected plasma concentrations at steady state. Six normal volunteers from the previous study (steady state) volunteered to participate in the single-dose study. Plasma concentrations were determined for 24 hr following a single dose of nadolol, 80 mg. A simple, inexpensive, and accurate method for determination of nadolol in plasma or serum by HPLC with fluorometric detection is described. The AUC0-tau at steady state was greater than the AUC0-infinity following a single dose in five of the six subjects. The mean ratio of AUCss/AUCsd was 2.54. This value would be unity in the presence of linear pharmacokinetics. We conclude that the principle of superposition is not applicable for nadolol.
Krukemyer
J J
JJ
Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis.
Boudoulas
H
H
Binkley
P F
PF
Lima
J J
JJ
D000328:Adult; D001682:Biological Availability; D006801:Humans; D008297:Male; D009248:Nadolol / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
D009248:Nadolol